-+ 0.00%
-+ 0.00%
-+ 0.00%

Fresenius Medical Care (XTRA:FME) Faces A Valuation Test As Earnings Outlook Tightens

Simply Wall St·11/16/2026 01:21:46
Listen to the news

Fresenius Medical Care (XTRA:FME) just paired a softer third quarter with a tighter full year earnings outlook, flagging operating income that could be flat or slightly lower even as revenue guidance stays broadly unchanged.

At a share price of €40.11, Fresenius Medical Care has seen short term momentum soften, with a 7 day share price return of a 5.02% decline and a 90 day share price return of a 1.67% decline. This comes even though the 1 year total shareholder return is 3.12% and the 3 year total shareholder return is 23.18%. This suggests investors are reassessing the risk profile after the weaker quarter and cautious guidance, while the recent share buyback program adds a separate support factor in the background.

Scan 206 resilient stocks with low risk scores that have been hand-picked for resilient balance sheets and steadier earnings profiles if Fresenius Medical Care's flatter outlook has you reconsidering where you take risk.

Fresenius Medical Care now trades just above the average analyst target, yet screens at a wide intrinsic discount. After a weaker quarter and softer outlook, is that caution still warranted or starting to overrun the fundamentals?

Most Popular Narrative: 4% Undervalued

Fresenius Medical Care's most followed narrative on Simply Wall St pegs fair value at €41.69, slightly above the recent €40.11 close. It frames that gap through the lens of cost savings, value based care and capital returns in the analyst consensus Narrative on Simply Wall St.

The FME25+ transformation program has already generated €804 million of sustainable savings and is now targeted to reach a total of €1.2b through 2027. Continued cost reductions and structural optimization are positioned to have a direct impact on operating margin and earnings quality.

See why 22 investors see Fresenius Medical Care as 4% undervalued.

Result: Fair Value of €41.69 (UNDERVALUED)

Still, elevated U.S. patient mortality, missed treatments and the recent FDA warning letter could restrain Fresenius Medical Care’s recovery story if costs and volumes remain under pressure.

Find out about the key risks to this Fresenius Medical Care narrative.

Next Steps

Mixed messages in the Fresenius Medical Care story, with clear risks alongside meaningful potential rewards, make this a moment to look closely and move decisively. To weigh both sides for yourself, start with the 5 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Fresenius Medical Care?

If Fresenius Medical Care has sharpened your focus on risk, this may be a good time to broaden your opportunity set with targeted, data driven stock ideas.